Reprint
Novel Biomarkers in Alzheimer’s Disease
Edited by
February 2021
442 pages
- ISBN978-3-03943-903-4 (Hardback)
- ISBN978-3-03943-904-1 (PDF)
This book is a reprint of the Special Issue Novel Biomarkers in Alzheimer’s Disease that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Alzheimer’s disease (AD) represents the most common form of dementia in the elderly population worldwide. AD is characterized by progressive neurodegeneration that leads to a gradual deterioration of memory and other cognitive functions. Given the global prevalence and impact of AD, there is a critical need to establish biomarkers that can be used to detect AD in individuals before the onset of clinical signs and provide mitigating therapeutics. The aim of this Special Issue is to discuss the current knowledge as well as future perspectives on the role of biomarkers in the screening, diagnosis, treatment and follow-up of AD.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
flotillin; Alzheimer’s disease; biomarker; exosomes; beta-amyloid; Tau; aging; biomarkers; cytokines; cognitive decline; Alzheimer’s disease; metabolomics; neuroinflammation; multivariate analysis; physical performance; person-tailored; Alzheimer’s disease; PET/CT; (18F)FDG; neuropsychological assessment; Alzheimer’s disease; APP mutations; APOE alleles; PSEN1; PSEN2; germline mutations; late onset AD; early onset AD; familial AD; genetics of AD; Alzheimer’s disease; mitochondrial spare respiratory capacity; mitochondrial; membrane potential; glycolytic reserve; semantic memory; phonemic fluency; episodic memory; neuropsychology; neuroimaging; Alzheimer's disease; mild cognitive impairment; EEG; TMS; obesity; diabetes; inflammation; Alzheimer’s disease; Amyloid Beta; Tau; biomarker; mitochondrial dysfunction; mild cognitive impairment; nutrition; omega-3 fatty acids; antioxidant; carotenoids; vitamin E; cognition; episodic memory; older adults; ageing; Alzheimer’s disease; subjective cognitive decline; mild cognitive impairment; clock genes; Clock; ApoE; cardiovascular risk factors; Alzheimer disease; semantic priming; mild cognitive impairment; Alzheimer’s disease; biomarker; amyloid beta; neuroimaging; cerebrospinal fluid; Alzheimer’s disease; cerebrospinal fluid; amyloid beta peptide; total tau; phosphorylated tau; diagnosis; Alzheimer’s disease; biomarkers; drug development; clinical trials; diagnostic research; Alzheimer’s disease; virus; bacteria; dementia; Alzheimer’s disease; biomarker; cerebrospinal fluid; blood; behavioral and psychological symptoms of dementia (BPSD); Alzheimer’s disease (AD); neuropsychiatry inventory scale (NPI); endophenotypes; CART analysis; MTHFR; APOE; COMT; genetic variants; Alzheimer’s disease; biomarkers; early diagnosis; biofluids; amyloid cascade hypothesis; glucose metabolism; adipose tissue dysfunction; energetic metabolism; lysosomes dysfunction; Type-3-Diabetes; neuroinflammation; neurodegeneration; Alzheimer’s disease; biomarkers; cerebrospinal fluid; blood; amyloid; tau; soluble TREM2; NfL; Multiplex; SiMoA; Alzheimer’s disease (AD); biomarkers; diagnostics; messenger RNA; microRNA; neuroimaging; neurotropic microbes; precision medicine; prognostics; biomarkers; Alzheimer’s disease; neurodegeneration; cerebrospinal fluid; mild cognitive impairment; synaptic biomarkers; neuroinflammation; neurofilament light chain; n/a